Cannabis

Weed and gold, the unloved investment thematics

Next Investors Oct 22, 2022

We have all seen when a new investment theme goes through an initial period of hype, the peak of inflated expectations and then the trough of disillusionment. Today we will look at how this hype cycles affects to investment themes we are closely watching for 2023: Weed and Gold

Bod Australia outlines strong revenue growth

Finfeed Archived Apr 22, 2021

Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX: BDA) has provided its shareholders an update for the Q3FY2021 quarter, ended 31 March 2021.

Move to legalisation of psychedelics could benefit CPH in the US

Finfeed Archived Apr 19, 2021

Creso Pharma Limited’s (ASX:CPH, FRA:1X8) target acquisition company Halucencex Life Sciences Inc. has signed a non-binding Letter of Intent (LOI) with leading nanotechnology company Sixth Wave Inc. as California pushes to decriminalise psychedelics, which highlights the ongoing acceptance and regulatory shift towards psychedelics as an alternative treatment route for debilitating mental health conditions.

Creso Pharma’s target acquisition company announces expansion into other psychedelic compounds

Finfeed Archived Apr 12, 2021

Creso Pharma Limited (ASX: CPH, FRA:1X8) has provided an update regarding target acquisition company, Halucenex Life Sciences, outlining its entry into an advisory agreement with Growing Together Research Inc. (GTR) to explore the genome sequencing of natural psilocybe.

CPH looks to expand its footprint as NY State reaches deal legalise recreational cannabis

Finfeed Archived Apr 06, 2021

Creso Pharma (ASX: CPH) has appointed a US Director of Business Development just as New York State has legalised recreational cannabis. New York State is expected to become one of the largest recreational markets in the US valued at US$4.2BN.

Revenue generating BDA sets its sights on US market

Finfeed Archived Mar 17, 2021

Bod Australia (ASX: BDA) is a cannabis centric healthcare company, with well-branded premium, proven and trusted products within two distinct verticals: Medical Cannabis and CBD and Hemp Consumer products.

Neurotech to commence clinical study program this quarter

Finfeed Archived Feb 15, 2021

Following the successful in vitro findings, Neurotech (ASX: NTI) has begun designing a phase I/II study to assess the safety and efficacy of the novel NTI/Dolce strain in a paediatric population.

Creso Pharma leads the way in burgeoning cannabis market

Finfeed Archived Jan 29, 2021

Creso Pharma looks set to start the year on a strong note after an impressive performance in the December quarter of 2020

Canopy Growth Founder Joins a Refreshed, Re-Set and Re-Funded CPH

Next Investors Archived Oct 13, 2020

While Creso Pharma (ASX: CPH) continues to sign purchase orders and has appointed Bruce Linton as an advisor, it is a highly speculative investment, and our intent is to hold for the coming months through to Christmas to see how the company’s strategy plays out.

Page 1 of 13 next >